Friday 10th November 2017
|Text too small?|
ASX-listed Kiwi biotech firm Living Cell Technologies' shares plunged 84 percent after the company said it won't immediately be seeking provisional consent for its treatment for Parkinson's disease when its latest trial did not show a "statistically significant difference" between people who received the treatment and a control group.
The Melbourne-based company halted trading of its shares yesterday ahead of the trial's results, which it was hoping would give it the all-clear to pursue commercial sales of its treatment as early as next year. The ASX-listed shares fell to 3.3 Australian cents from 20.5 Australian cents after the news.
"More data analysis and input from our advisers is required but at this time we cannot proceed with a regulatory application," chief executive Ken Taylor said in a statement to the ASX.
Living Cell developed the NTCELL treatment for Parkinson’s disease using choroid plexus brain cells from neonatal pigs, which are implanted into a damaged site in the brain and then function as a “neurochemical factory” producing factors that promote new central nervous system growth and repair disease-induced nerve degeneration.
The cell therapy had shown potential in early trials as a disease-modifying agent in Parkinson’s disease. The latest study was designed to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient subgroup. The biotech firm's Phase IIb clinical trial was completed in April and it had been waiting for the results to be unblinded,
There were three groups of six patients and two patients from each group had sham surgery with no NTCELL implanted, to act as a control. The remaining patients received different numbers of microcapsules of NTCELL on each side of the brain.
While no product or procedure adverse events occurred and there is no evidence of xenogeneic infection in patients and their partners "we are disappointed that the efficacy primary endpoint has not been met," said Taylor.
Principal investigator Barry Snow at Auckland City Hospital said the next step is to analyse the data in depth and continue to monitor patients in accord with the study extension protocol, particularly for the efficacy movements at longer time points.
No comments yet
Gold price hits $2,000 for first time on Covid
TruScreen strengthens its market presence in central and eastern Europe
Refining NZ announces non-cash impairment
Ryman Healthcare COVID-19 update Victoria
Talisman Quarterly Activities Report to 30 June 2020
General Capital gives notice of Annual Meeting
Scales Corporation - Business Update
Fonterra Co-operative Group Global Dairy Update
Fonterra revises its 2019/20 and 2020/21 forecast Farmgate Milk Price ranges
Briscoe Group Limited Market update: 2nd Quarter Sales to 26 July 2020